BioMarin

BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia

SAN RAFAEL, Calif., March 3, 2021 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has completed full enrollment in... Read More
BioMarin
Hypochondroplasia
Skeletal Dysplasia

Study may change treatment of childhood growth disorders

A child’s growth is often measured by pediatricians during routine physicals to identify abnormalities of growth and stature. An... Read More